Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Overview
    • Patients
    • ABX464 for UC
    • ABX464 for Crohn’s
    • ABX464 for RA
    • ABX464 for COVID-19
    • ABX464 for HIV
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • Annual General Meeting
  • Contact Us
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017

Healio

December 20, 2017

ABX464 reduces HIV reservoir

PharmaVoice

November 22, 2017

Trending 2018 : Treatment to Wellness

EBD Group

November 22, 2017

BIO-Europe® 2017: Abivax CEO highlights pipeline assets, including lead HIV drug

BioCentury

October 6, 2017

ABIVAX’S ABX464 REDUCES HIV DNA IN CD4+ T CELLS IN PHASE IIA

LabioTech

September 28, 2017

Study Results Confirm that Abivax’s HIV Cure Gets Rid of Virus

  • 1
  • 2
  • 3
  • 4
© 2021 All rights reserved by ABIVAX | Website created by DIGITAL VALLEE Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • ABX464 for UC
    • ABX464 for HIV
    • ABX196 for HCC
    • ABX544 for Ebola Virus
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • Annual General Meeting
    • UEG Week 2019
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+